Search results for "pharmacology [Benzodiazepinones]"

showing 10 items of 169 documents

Technical Note on the quality of DNA sequencing for the molecular characterisation of genetically modified plants

2018

Abstract As part of the risk assessment (RA) requirements for genetically modified (GM) plants, according to Regulation (EU) No 503/2013 and the EFSA guidance on the RA of food and feed from GM plants (EFSA GMO Panel, 2011), applicants need to perform a molecular characterisation of the DNA sequences inserted in the GM plant genome. The European Commission has mandated EFSA to develop a technical note to the applicants on, and checking of, the quality of the methodology, analysis and reporting covering complete sequencing of the insert and flanking regions, insertion site analysis of the GM event, and generational stability and integrity. This Technical Note puts together requirements and r…

0106 biological sciences0301 basic medicineVeterinary (miscellaneous)[SDV]Life Sciences [q-bio]2405 Parasitologymolecularcharacterisationnext‐generation sequencingContext (language use)Plant ScienceComputational biologyGenetically modified cropsBiology01 natural sciencesMicrobiologyGenomeInsert (molecular biology)DNA sequencing03 medical and health sciencessymbols.namesake1110 Plant Sciencegenetically modified organismgenetic stabilityDNA sequencing1106 Food ScienceSanger sequencinggenetically modified organisms2404 Microbiologyrisk assessmentmolecular characterisation10079 Institute of Veterinary Pharmacology and ToxicologyGenetically modified organism3401 Veterinary (miscellaneous)Scientific Opinion030104 developmental biologyNGSsymbols570 Life sciences; biologyAnimal Science and ZoologyParasitologynext-generation sequencing1103 Animal Science and Zoology010606 plant biology & botanyFood ScienceVerification and validation
researchProduct

Annual post-market environmental monitoring (PMEM) report on the cultivation of genetically modified maize MON 810 in 2014 from Monsanto Europe S.A.

2016

Requestor: European CommissionQuestion number: EFSA-Q-2015-00650; Following a request from the European Commission, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) assessed the annual post-market environmental monitoring (PMEM) report for the 2014 growing season of maize MON 810 provided by Monsanto Europe S.A. The GMO Panel concludes that the insect resistance monitoring data do not indicate a decrease in susceptibility of field Iberian populations of corn borers to the Cry1Ab protein over the 2014 season. However, as the methodology for insect resistance monitoring remained unchanged compared to previous PMEM reports, the GMO Panel reiterates …

0106 biological sciencesSettore BIO/07 - EcologiaVeterinary (miscellaneous)[SDV]Life Sciences [q-bio]TP1-1185Plant Science010501 environmental sciencesZea mays01 natural sciencesMicrobiologycase‐specific monitoringCry1Ab case-specific monitoring farmer questionnaires general surveillance insect resistance management Zea maysTX341-641Cry1Ab0105 earth and related environmental sciences2. Zero hungerNutrition. Foods and food supplyChemical technologyfungigeneral surveillance10079 Institute of Veterinary Pharmacology and Toxicologyfarmer questionnairesinsect resistance managementSettore AGR/02 - Agronomia E Coltivazioni ErbaceeSettore AGR/11 - Entomologia Generale E Applicata570 Life sciences; biologyAnimal Science and ZoologyParasitology010606 plant biology & botanyFood Science
researchProduct

Guidance for the risk assessment of the presence at low level of genetically modified plant material in imported food and feed under Regulation (EC) …

2017

Abstract This document provides guidance for the risk assessment under Regulation (EC) No 1829/2003 of the unintended, adventitious or technically unavoidable presence in food and feed of low level of genetically modified plant material intended for markets other than in the European Union. In this context, the presence at low level is defined to be maximum 0.9% of genetically modified plant material per ingredient. This guidance is intended to assist applicants by indicating which scientific requirements of Annex II of Regulation (EU) No 503/2013 are considered necessary for the risk assessment of the presence at low levels of genetically modified plant material in food and feed.

0106 biological sciencesVeterinary (miscellaneous)[SDV]Life Sciences [q-bio]Context (language use)Plant ScienceGenetically modified crops010501 environmental sciences01 natural sciencesMicrobiologyRegulation (EU) No 503/2013Ingredientpresence at low level[SDV.IDA]Life Sciences [q-bio]/Food engineeringmedia_common.cataloged_instance[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySettore AGR/18 - Nutrizione E Alimentazione Animale[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringEuropean unionfood/feed0105 earth and related environmental sciencesmedia_commonguidance;GMO;presence at low level;risk assessment;Regulation (EC) No 1829/2003;Regulation (EU) No 503/2013;food/feedbusiness.industryGMORegulation (EC) No 1829/2003risk assessmentguidance; GMO; presence at low level; risk assessment; Regulation (EC) No 1829/2003; Regulation (EU) No 503/2013; food/feed10079 Institute of Veterinary Pharmacology and ToxicologyFood safetyBiotechnologyRegulation (EU) No 503/2013Scientific OpinionSettore AGR/11 - Entomologia Generale E Applicata570 Life sciences; biologyAnimal Science and ZoologyParasitologyRisk assessmentbusinessguidanceRegulation (EC) No 1829/2003010606 plant biology & botanyFood Science
researchProduct

Assessment of genetically modified maize GA21 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐005)

2017

Efsa Panel On Genetically Modified Organisms (gmo) Requestor: European Commission (DG SANTE)Question number: EFSA-Q-2016-00714Correspondence; Following the submission of application EFSA-GMO-RX-005 under Regulation (EC) No 1829/2003 from Syngenta Crop Protection NV/SA, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant genetically modified maize GA21. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic search and eval…

0106 biological sciencesmaïsVeterinary (miscellaneous)[SDV]Life Sciences [q-bio]Context (language use)TP1-1185Plant Science010501 environmental sciencesOriginal Applicationmaize01 natural sciencesMicrobiologyGenetically modified soybeanzea maysGA21articles 11 and 23media_common.cataloged_instanceTX341-641European union0105 earth and related environmental sciencesmedia_common2. Zero hungerrenewalNutrition. Foods and food supplybusiness.industryindian cornChemical technologyfungiAuthorizationRegulation (EC) No 1829/200310079 Institute of Veterinary Pharmacology and ToxicologyFood safetyGenetically modified organismBiotechnologyScientific Opinionmaize;GA21 renewal;Regulation (EC) No 1829/2003;articles 11 and 23Regulation (EC) No1829/2003570 Life sciences; biologyAnimal Science and ZoologyParasitologyRisk assessmentbusinessRegulation (EC) No 1829/2003010606 plant biology & botanyFood Science
researchProduct

As-needed anti-inflammatory reliever therapy for asthma management: evidence and practical considerations

2021

Asthma is a chronic respiratory disease in which airway inflammation is a key feature, even in the milder expressions of the disease. The conventional pharmacological approach to mild asthma has long relied on reliever therapy with as-needed short-acting beta-agonists (SABAs), while anti-inflammatory maintenance with inhaled corticosteroids (ICSs) has been reserved for patients with more persistent asthma. Poor adherence to maintenance treatment is an important issue in asthma management, and can partly explain suboptimal symptom control. Over-reliance on SABA bronchodilators for rapid symptom relief is common in real life and potentially leads to an increased risk of asthma morbidity and m…

0301 basic medicineBudesonidemedicine.medical_specialtyImmunologySettore SECS-P/03Anti-Inflammatory AgentsSocio-culturaleDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthma managementasthma; pharmacology and pharmacogenomics; pneumology03 medical and health sciences0302 clinical medicineSymptom reliefMaintenance therapymedicineImmunology and AllergyHumansAnti-Asthmatic AgentsPneumologyIntensive care medicineAsthmaAsthma Pharmacology and pharmacogenomics Pneumologybusiness.industryInhalerPharmacology and pharmacogenomicsRespiratory diseasepharmacology and pharmacogenomicmedicine.diseaseAsthmarespiratory tract diseasesBronchodilator Agents030104 developmental biology030228 respiratory systembusinessmedicine.drug
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Increased Motor-Impairing Effects of the Neuroactive Steroid Pregnanolone in Mice with Targeted Inactivation of the GABAA Receptor γ2 Subunit in the …

2016

Endogenous neurosteroids and neuroactive steroids have potent and widespread actions on the brain via inhibitory GABAA receptors. In recombinant receptors and genetic mouse models their actions depend on the α, β, and δ subunits of the receptor, especially on those that form extrasynaptic GABAA receptors responsible for non-synaptic (tonic) inhibition, but they also act on synaptically enriched γ2 subunit-containing receptors and even on αβ binary receptors. Here we tested whether behavioral sensitivity to the neuroactive steroid agonist 5β-pregnan-3α-ol-20-one is altered in genetically engineered mouse models that have deficient GABAA receptor-mediated synaptic inhibition in selected neuro…

0301 basic medicineGAMMA-2-SUBUNITCerebellumNeuroactive steroidcerebellumDISORDERSPurkinje cellINHIBITIONBiologyPharmacologyGABAA-rho receptor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCRE RECOMBINASE EXPRESSIONmedicinePharmacology (medical)Pharmacology & PharmacyReceptorPARVALBUMIN-POSITIVE INTERNEURONSIN-VIVOOriginal ResearchPregnanolonePharmacologyScience & TechnologyGABAA receptorAllopregnanolonelcsh:RM1-950POINT MUTATIONA RECEPTORS3. Good health030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. Pharmacologychemistrynervous systemPurkinje cellsALLOPREGNANOLONEextrasynaptic GABAA receptorsmotor performance1115 Pharmacology And Pharmaceutical Sciences3111 BiomedicineneurosteroidsLife Sciences & Biomedicine030217 neurology & neurosurgeryextrasynaptic GABA(A) receptors
researchProduct

Ferroptosis and Its Potential Role in Human Diseases

2020

Ferroptosis is a novel regulated cell death pattern discovered when studying the mechanism of erastin-killing RAS mutant tumor cells in 2012. It is an iron-dependent programmed cell death pathway mainly caused by an increased redox imbalance but with distinct biological and morphology characteristics when compared to other known cell death patterns. Ferroptosis is associated with various diseases including acute kidney injury, cancer, and cardiovascular, neurodegenerative, and hepatic diseases. Moreover, activation or inhibition of ferroptosis using a variety of ferroptosis initiators and inhibitors can modulate disease progression in animal models. In this review, we provide a comprehensiv…

0301 basic medicineProgrammed cell deathReviewdegenerative diseasesBiologyHepatic Diseases03 medical and health sciences0302 clinical medicineRegulated cell deathmedicinePharmacology (medical)Pharmacologyreactive oxygen speciesMechanism (biology)Ferroptosislcsh:RM1-950Disease progressionCancermedicine.diseaseferroptosissignaling pathwayslcsh:Therapeutics. Pharmacology030104 developmental biologypharmacology design030220 oncology & carcinogenesisCancer researchSignal transductionFrontiers in Pharmacology
researchProduct

Assessment of genetically modified maize NK603 x MON810 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐007)

2018

Efsa Panel On Genetically Modified Organisms (gmo)Scientific opinionRequestor:European Commission (DG SANTE)Question number:EFSA-Q-2017-00028; Following the submission of application EFSA-GMO-RX-007 under Regulation (EC) No 1829/2003 from Monsanto, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant and insect-resistant genetically modified maize NK603 x MON810. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic searc…

0301 basic medicinemaïsVeterinary (miscellaneous)gmo[SDV]Life Sciences [q-bio]2405 ParasitologyogmTP1-1185Plant SciencemaizeMicrobiologyzea mays03 medical and health sciences0404 agricultural biotechnology1110 Plant Sciencearticles 11 and 23TX341-6411106 Food ScienceNK603xMON8102. Zero hungerrenewal030109 nutrition & dieteticsNutrition. Foods and food supplymaize; NK603xMON810; renewal; articles 11 and 23; Regulation (EC) No1829/2003indian cornChemical technology2404 MicrobiologyRegulation (EC) No 1829/2003maize;NK603 x MON810;renewal;articles 11 and 23;Regulation (EC) No 1829/2003NK603 x MON81010079 Institute of Veterinary Pharmacology and Toxicology04 agricultural and veterinary sciences040401 food scienceSettore AGR/02 - Agronomia E Coltivazioni Erbacee3401 Veterinary (miscellaneous)Scientific OpinionSettore AGR/11 - Entomologia Generale E ApplicataRegulation (EC) No1829/2003570 Life sciences; biologyAnimal Science and ZoologyParasitology1103 Animal Science and ZoologyNK603 x MON810Regulation (EC) No 1829/2003Food Science
researchProduct

Metabolic detoxification: implications for thresholds.

2000

The fact that chemical carcinogenesis involves single, isolated, essentially irreversible molecular events as discrete steps, several of which must occur in a row to finally culminate in the development of a malignancy, rather suggests that an absolute threshold for chemical carcinogens may not exist. However, practical thresholds may exist due to saturable pathways involved in the metabolic processing, especially in the metabolic inactivation, of such compounds. An important example for such a pathway is the enzymatic hydrolysis of epoxides via epoxide hydrolases, a group of enzymes for which the catalytic mechanism has recently been established. These enzymes convert their substrates via…

040301 veterinary sciencesDNA damageEpoxide10050 Institute of Pharmacology and Toxicology610 Medicine & healthToxicology030226 pharmacology & pharmacyPathology and Forensic MedicineXenobiotics0403 veterinary science1307 Cell Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnzymatic hydrolysis1312 Molecular BiologyAnimalsHumansComputer SimulationEpoxide hydrolaseMolecular BiologyCarcinogenchemistry.chemical_classificationEpoxide HydrolasesDose-Response Relationship Drug3005 Toxicology04 agricultural and veterinary sciencesCell Biology2734 Pathology and Forensic MedicineEnzymechemistryBiochemistryCovalent bondEpoxide HydrolasesInactivation MetabolicCarcinogensMicrosomes Liver570 Life sciences; biologyMutagensToxicologic pathology
researchProduct